News | May 24, 2024
BaseLaunch announces a new partnership with AbbVie
Further strengthens BaseLaunch's global pharma industry partnerships
Further strengthens BaseLaunch's global pharma industry partnerships
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Establishing Asymchem’s first manufacturing footprint in Europe
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Subscribe To Our Newsletter & Stay Updated
